Novel Therapeutic Approaches to Liver Fibrosis Based on Targeting Oxidative Stress
Antioxidants · 05.08.2023 · 12 (8) · 1567
DOI: 10.3390/antiox12081567 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Antioxidants, online erschienen am 05.08.2023. Verfasst von Ana Blas-García und 1 weiteren Autor:innen. Beteiligte Einrichtung: Departamento de Fisiología, Universitat de València, Av. Blasco Ibáñez, 15, 46010 Valencia, Spain. Die Arbeit wurde bisher 46-mal zitiert (Crossref) und nennt 127 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Instituto de Salud Carlos III, Generalitat Valenciana, Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana.
Abstract (Originalsprache)
Chronic liver disease (CLD) constitutes a growing global health issue, with no effective treatments currently available. Oxidative stress closely interacts with other cellular and molecular processes to trigger stress pathways in different hepatic cells and fuel the development of liver fibrosis. Therefore, inhibition of reactive oxygen species (ROS)-mediated effects and modulation of major antioxidant responses to counteract oxidative stress-induced damage have emerged as interesting targets to prevent or ameliorate liver injury. Although many preclinical studies have shown that dietary supplements with antioxidant properties can significantly prevent CLD progression in animal models, this strategy has not proved effective to significantly reduce fibrosis when translated into clinical trials. Novel and more specific therapeutic approaches are thus required to alleviate oxidative stress and reduce liver fibrosis. We have reviewed the relevant literature concerning the crucial role of alterations in redox homeostasis in different hepatic cell types during the progression of CLD and discussed current pharmacological approaches to ameliorate fibrosis by reducing oxidative stress focusing on selective modulation of enzymatic oxidant sources, antioxidant systems and ROS-mediated pathogenic processes.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Departamento de Fisiología, Universitat de València, Av. Blasco Ibáñez, 15, 46010 Valencia, Spain.
- FISABIO (Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunidad Valenciana), Av. de Catalunya, 21, 46020 Valencia, Spain.
- CIBERehd (Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas), Instituto de Salud Carlos III, Monforte de Lemos, 3-5, 28029 Madrid, Spain.
- Departamento de Farmacología, Universitat de València, Av. Blasco Ibáñez, 15, 46010 Valencia, Spain.
ORCID-Profile: Ana Blas-García, Nadezda Apostolova
Förderung
- Instituto de Salud Carlos III
- Generalitat Valenciana
- Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana
- Ministerio de Ciencia e Innovación, Spain
- CIBER -Consorcio Centro de Investigación Biomédica en Red-
- FISABIO
- Ministerio de Ciencia e Innovación/Agencia Española de Investigación /10.13039/501100011033/FEDER, UE
Zitieren
APA
Blas-García, A., & Apostolova, N. (2023). Novel Therapeutic Approaches to Liver Fibrosis Based on Targeting Oxidative Stress. Antioxidants, 12(8), 1567. https://doi.org/10.3390/antiox12081567
Vancouver
Blas-García A, Apostolova N. Novel Therapeutic Approaches to Liver Fibrosis Based on Targeting Oxidative Stress. Antioxidants. 2023;12(8):1567. doi:10.3390/antiox12081567
BibTeX
@article{BlasGarca2023,
author = {Blas-García, Ana and Apostolova, Nadezda},
title = {Novel Therapeutic Approaches to Liver Fibrosis Based on Targeting Oxidative Stress},
journal = {Antioxidants},
year = {2023},
volume = {12},
number = {8},
pages = {1567},
doi = {10.3390/antiox12081567}
}
EUVIMED